gene therapy

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Dyno attracts $1.6bn gene therapy deal with Astellas

Astellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics to tap into its adeno-associated virus (AAV) vector platform for deliveri

News

Sanofi winds $40m into UK gene therapy firm Gyroscope

French drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on offer as the UK biotech advances its clinical-stage gene therapi

News

Astellas reports fourth death in halted gene therapy trial

There has been a fourth patient fatality in Astellas' clinical trial of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM), which has been halted twice due to

News

AbbVie spies potential in Regenxbio eye disease gene therapy

AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for wet age-related macular degeneration (

News

DNA helix in a futuristic concept of the evolution of science and medicine.

FDA slaps clinical hold on BioMarin's PKU gene therapy

BioMarin Pharma has had another setback in its gene therapy development programme, announcing this morning that the FDA has placed a phase 1/2 trial of its candidate for phenylketonuria (PK

News

More trouble for Astellas as AT132 gene therapy trial is hal...

Astellas has halted dosing in a study of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM) for the second time after another serious adverse event (SAE) linke

Dyno attracts $1.6bn gene therapy deal with Astellas

Sanofi winds $40m into UK gene therapy firm Gyroscope

Astellas reports fourth death in halted gene therapy trial

AbbVie spies potential in Regenxbio eye disease gene therapy

FDA slaps clinical hold on BioMarin's PKU gene therapy

More trouble for Astellas as AT132 gene therapy trial is hal...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

gene therapy

Editor's Picks